Sequential RCHOP and yttrium-90 ibritumomab tiuxetan (RIT) is a highly effective regimen for high risk elderly patients with untreated DLBCL Meeting Abstract

  

Authors:	Hamlin, P. A.; Moskowitz, C. H.; Wegner, B.; Noy, A.; Gerecitano, J.; Palomba, M. L.; Portlock, C.; Straus, D.; Pro, B.; Fayad, L.; Rodriguez, A.; Zelenetz, A. D.
Abstract Title:	Sequential RCHOP and yttrium-90 ibritumomab tiuxetan (RIT) is a highly effective regimen for high risk elderly patients with untreated DLBCL
Meeting Title:	10th International Conference on Malignant Lymphoma
Journal Title:	Annals of Oncology
Volume:	19
Issue:	Suppl. 4
Meeting Dates:	2008 Jun 4-7
Meeting Location:	Lugano, Switzerland
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2008-06-01
Start Page:	100
Language:	English
ACCESSION:	WOS:000256693500070
PROVIDER:	wos
DOI:	10.1093/annonc/mdn215
Notes:	--- - Meeting Abstract: 054 - 10th International Conference on Malignant Lymphoma - JUN 04-07, 2008 - Lugano, SWITZERLAND - "4" - "Source: Wos"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/24134